Twenty-two susceptible strains of Haemophilus influenzae were examined for mutation to rifampin resistance (minimal inhibitory concentration, :10 ,ug/ml). All strains had detectable apparent mutation frequencies with a median minimal inhibitory concentration 2,000-fold greater than that of their wild-type parents. Of the type b strain mutants, 80%o (8 of 10) expressed high-level resistance (minimal inhibitory concentration, 750 ,ug/ml) that was 75-fold greater than readily achievable serum concentrations.
Rifampin administration has been advocated to eliminate nasopharyngeal carriage of Haemophilus influenzae type b and to prevent secondary cases in susceptible contacts (4) . A hazard of chemoprophylaxis is the emergence of resistant organisms, as has been shown for meningococci (3) . Two reports have documented the emergence of rifampin-resistant (Rifr) H. influenzae in children who received rifampin prophylactically (8, 9) . We had noted a significant number of Rifr mutants in conjugation experiments, which prompted us to examine 22 Rif' strains, selected on the bases of capsulation status, biotype, and concomitant antibiotic resistance, for their apparent frequency of spontaneous mutation to this resistant phenotype. Rifr mutants were tested for their susceptibility to the drug and examined for the stability of the resistance. A total of 20 clinical H. intfluenzae isolates (10 with and 10 without detectable type b capsule) of varying antibiotic susceptibility and biotype were examined. Two laboratory derivatives of strains Rd (10) used extensively in genetic studies were also evaluated, one without antibiotic resistance markers (strain Good Rd [11] ) and the other (strain super 8) resistant to eight antibiotics, including erythromycin (2). All strains had obligatory requirements for j-NAD and hemin for growth when incubated at 37°C in room air. All strains identified as type b agglutinated with two commercial anti-type b sera (Difco Laboratories and Hyland Laboratories, Inc.) and had a precipitin reaction on antiserum agar (7). Untypable strains were not irridescent on translucent media and did not agglutinate with Difco typing sera a through f.
The solid medium used for growth of H.
influenzae and determination of the minimal inhibitory concentration (MIC) was GC medium base agar (Difco) supplemented with 10 ,ug of Lhistidine, 10 ag of hemin, and 2 ,ug of NAD+ per ml and containing 1% of Kellog's supplement GC agar (40%o glucose-0.5% glutamine-0.05% ferric nitrate-0.001% thiamine pyrophosphate in water [1] ). The solid medium was supplemented with 10 ,ug of rifampin per ml for selection of Rif' mutants. Brain heart infusion broth (Difco Laboratories) supplemented with 10 ,ug of hemin, 10 pug of L-histidine, and 2 ,ug of NAD+ per milliliter was used for liquid cultures. Plate cultures were incubated at 36.5°C in 5% C02, whereas liquid cultures were incubated at 37°C in room air and shaken at 200 rotations per min. All strains were biotyped by the classification of Kiian (5) by the Minitek method of Back and Oberhofer (1) .
The concentrations of rifampin in GC agar used when testing the parent strain were 0.05, 0.1, 0.25, 0.5, 1, 5, and 10 ,ug/ml; those used for testing mutant strains were 1, 5, 10, 20, 40, 60, 80,100, 250, 500, 750, and 1,000 Fg/ml. The MIC was defined as the lowest concentration of antibiotic which inhibited visible growth of the inoculum in comparison with growth on antibioticfree media. The plates were examined after 18 to 24 h of incubation in 5% CO2 at 36.5°C. The inocula tested were 107, 106, 105, 104, 1 and 102 colony-forming units (CFU).
Strains were harvested from overnight growth on solid media, inoculated into 6 ml of supplemented brain heart infusion broth, and allowed to grow to a cell density of approximately 109 CFU per ml (3 h); 0.1-ml samples were plated on GC agar containing 10 ,ug of rifampin per ml. At least nine replicates of each strain were plated in two separate experiments; parallel dilutions were plated on antibiotic-free plates to deter-mine the bacterial density. The mutation frequencies were determined from the total number of mutant CFU divided by the total number of CFU plated. One mutant colony from each strain was selected for MIC determination; two mutants from two type b strains were tested.
Eight of the Rif' mutant colonies, four type b (two with and two without other antibiotic resistance markers), two unencapsulated, and two laboratory strains were selected, grown in supplemented brain heart infusion broth to a cell density of 109 CFU/ml, and plated on antibioticfree solid media at a dilution to obtain individual colonies. A total of 125 colonies from each strain were then tested for stability of rifampin resistance by replicate plating to GC agar plates containing 10 ,ug of rifampin per ml. A random colony from each of these eight strains was also passed in broth culture with daily 1:20 dilutions in antibiotic-free media for 10 days. After 10 days, the cells were harvested and tested for rifampin susceptibility by agar dilution. A total of 100 colonies from each of these multiply passed strains were grown on antibiotic-free GC agar and then replicated to solid media containing rifampin at 10 ,ug/ml.
All All mutants were spontaneously derived, and there was no attempt at mutagenesis. Mutants were selected on agar containing a rifampin concentration (10 jig/ml) which was 40 times the MIC for the 22 strains. This selection concentration approximates maximum achievable serum concentration in children after an oral dose of 10 mg/kg (6) .
The MICs of the Rifr mutants ranged from 20 to 750 ,ug/ml; all but five had an MIC of >100 jig/ a Strain u produces no capsule with Difco antisera a through f.
b Single mutants were selected on agar containing 10 ,ug of rifampin per ml.
c Two different mutants tested.
ml with a 105 inoculum (Table 1) ; the median MIC was 500 ,ug/ml. This median MIC was 2,000-fold greater than that of the parents. Of the 22 strains, 17 (8 of the 10 type b strains) mutated to high-level resistance. All 1,000 colonies of the eight resistant mutants, were resistant to rifampin (10 ,ug/ml) before serial daily transfer. After multiple passage, only colonies from one mutant strain, derived from strain super 8, reverted to susceptibility (MIC, 0.5 pLg/ml). However, the MICs of all eight resistant mutants were unchanged (i.e., within one dilution). We have also found a high rate of reversion to erythromycin susceptibility in strain super 8 (unpublished data).
The litnitation of studying a single mutant colony from each strain must be emphasized.
Although two mutant strains from one type b strain had identical results, two mutants from another type b strain were inhibited by rifampin at concentrations of 20 and 250 ,ug/ml with an inoculum of 105 (Table 1) . Thus, more than one mechanism of resistance may be involved.
These data indicate that an appreciable mutation frequency to high-level resistance occurs in the laboratory. Prophylaxis with rifampin could lead to an increase in Rif' strains of H. influenzae carried by children. The virulence of these Rif' mutants and the stability of their resistance to rifampin should be studied. In addition, the mechanisms of high-and low-level resistance should be examined.
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